A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
研究单位：[1]Hoffmann-La Roche[2]Compassionate Care Research Group Inc. Corona,Corona,California,United States,92879[3]Compassionate Cancer Care Medical Group, Inc,Corona,California,United States,92882[4]Compassionate Care Research Group Inc. Riverside,Riverside,California,United States,92501[5]Florida Cancer Specialists - Fort Myers (Broadway),Fort Myers,Florida,United States,33901[6]Florida Cancer Specialist, North Region,Saint Petersburg,Florida,United States,33705[7]Mount Sinai Medical Center,New York,New York,United States,10029[8]Weill Cornell Medical College,New York,New York,United States,10065[9]Great Lakes Cancer Center,Williamsville,New York,United States,14221[10]MD Anderson Cancer Center[11]Oncology,Houston,Texas,United States,77030[12]Fundacion Favaloro,Buenos Aires,Argentina,C1093AAS[13]Instituto de Investigaciones Metabolicas (Idim),Ciudad Autonoma de Buenos Aires,Argentina,C1012AAR[14]Centro Oncologico Riojano Integral (CORI),La Rioja,Argentina,F5300COE[15]Princess Alexandra Hospital,Woolloongabba,Queensland,Australia,4102[16]Austin Health[17]Cancer Clinical Trial Centre,Heidelberg,Victoria,Australia,3084[18]St John of God Hospital[19]Bendat Cancer Centre,Subiaco,Western Australia,Australia,6008[20]Tiroler Landeskrankenanstalten Ges.M.B.H.[21]Innere Medizin Abt. Für Hämatologie & Onkologie,Innsbruck,Austria,6020[22]Klinikum Klagenfurt am Wörthersee[23]Abteilung für Innere Medizin und Onkologie,Klagenfurt am Wörthersee,Austria,9020[24]Ordensklinikum Linz Barmherzige Schwestern[25]Viszeralonkologisches Zentrum,Linz,Austria,4010[26]AKH - Medizinische Universität Wien[27]Department for Internal Medicine I,Wien,Austria,1090[28]UZ Antwerpen,Edegem,Belgium,2650[29]UZ Leuven Gasthuisberg,Leuven,Belgium,3000[30]CHU Sart-Tilman,Liège,Belgium,4000[31]Anyang Tumor Hosptial,Anyang City,China,455000[32]Cancer Hospital Chinese Academy of Medical Sciences.,Beijing,China,100021[33]Affiliated Hospital of Bengbu Medical College,Bengbu,China,233004[34]Hunan Cancer Hospital,Changsha CITY,China,410013[35]Heping Hospital Affiliated to Changzhi Medical College,Changzhi City,China,046000[36]Changzhou Cancer hospital,Changzhou,China,213000[37]Sichuan Provincial Cancer Hospital,Chengdu,China,610041[38]West China Hospital, Sichuan University,Chengdu,China,610041[39]Chongqing Sanxia Central Hospital,Chongqing City,China,404000[40]Chongqing Cancer Hospital,Chongqing,China,400030[41]Fujian Cancer Hospital,Fuzhou,China,350014[42]Sun Yet-sen University Cancer Center,Guangzhou City,China,510663[43]Nanfang Hospital, Southern Medical University,Guangzhou,China,510515[44]The First Affiliated Hospital of College of Medicine, Zhejiang University,Hangzhou,China,310003[45]Affiliated Drum Tower Hospital of Nanjing University Medical School[46]Nanjing Shi,Jiangsu Sheng,China,210008[47]Jieyang People''s Hospital,Jieyang City,China,522000[48]Shandong Cancer Hospital,Jinan,China,250117[49]Affiliated Hospital of Jining Medical University,Jining,China,272029[50]The First People''s Hospital of Lian Yun Gang,Lianyungang,China,222023[51]Lishui Central Hospital,Lishui City,China,323000[52]The First Affiliated Hospital to Henan University of Science and Technology,Luoyang City,China,471031[53]Jiangsu Cancer Hospital,Nanjing City,China,211100[54]Fudan University Shanghai Cancer Center[55]Medical Oncology,Shanghai City,China,201315[56]Shanghai Chest Hospital,Shanghai,China,200000[57]Cancer Hospital of Shantou University Medical College,Shantou,China,515041[58]Liaoning cancer Hospital & Institute,Shenyang,China,110042[59]Cancer Hospital Chinese Academy of Medical Sciences Shenzhen Center,Shenzhen City,China,518127[60]Hebei Medical University Fourth Hospital[61](Tumor Hospital of Hebei Province),Shijiazhuang,China,050035[62]Tianjin Cancer Hospital,Tianjin,China,300060[63]Wuhan Union Hospital Tongji Medical
研究目的：
The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy (dCRT). Participants will be randomized in a 1:1:1 ratio to receive either tiragolumab plus atezolizumab (Arm A), tiragolumab matching placebo plus atezolizumab (Arm B), or double placebo (Arm C).
